This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Confronted with the public outcry, the FDA took an unusual step: It allowed pharmacies to continue making their own copies of the drug through the practice of pharmacy compounding, selling it at a fraction of Makena’s price.
To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as GLP-1s. District Court for the Northern District of California. Continue to STAT+ to read the full story…
The deal marks a noteworthy development for Ro, which has been one of the major telehealth platforms providing compounded copies of GLP-1 obesity drugs during shortages of the branded treatments. Continue to STAT+ to read the full story…
The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Businesses are changing prescriptions, mixing in additives, or encouraging stockpiling of existing compounded products. Some have disappeared altogether.
Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.”
The move means that patients will no longer have access to cheaper versions from compounding pharmacies. Due to ongoing shortages of the Lilly drugs, compounding pharmacies were permitted to make copies that sold for substantially less.
Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies are legally allowed to make versions of branded treatments if the drugs are deemed to be in shortage by the FDA.
Over the past two years, patients seeking treatment have been turning to compounding pharmacies, which make cheaper copies of branded treatments and are legally allowed to do so only when the branded treatments are listed on the FDA’s shortage list.
Good morning, we’ve got a bunch of news this morning about GLP-1 drugs, compounding, and biotechs’ interactions with the FDA. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Let’s get into it. Read the rest…
Food and Drug Administration seeking to block compounding pharmacies in the U.S. We hope you have a meaningful and manageable day. Best of luck, and do keep in touch. … Novo Nordisk filed another citizen’s petition with the U.S. from making versions of one of its GLP-1 agonist drugs , Pharmaphorum notes.
… Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy as the U.S. Noom offers its compounded semaglutide at a starting price of $149 for the first month. milligram vial of Wegovy or Zepbound costs $349, according to the Novo and Lilly websites.
The agency will give compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients. That should have prohibited compounders from continuing to make copies, because they can do so only when a treatment is on the shortage list.
wrote that they worry that the Hims ad, which will be seen by millions of people during the big game on Sunday, “risks misleading patients by omitting any safety or side effect information” about the compounded weight loss drugs that it promotes. Dick Durbin (D-Ill.) and Roger Marshall (R-Kan.)
Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drugmakers compete for market share and try to draw patients away from compounding pharmacies that have been making cheaper copies of weight loss drugs.
The plants’ inability to remove compounds known as organofluorines from wastewater before they enter drinking water supplies becomes even more pronounced during droughts and could affect up to 23 million people. Most of the compounds came from commonly prescribed medications including antidepressants and statins.
Scientists in this field analyze the chemical compounds in plants, animals, and microorganisms to discover potential new drugs. From Plant to Patent: The Journey of Natural Compounds Now that we understand what pharmacognosy is, let’s explore how discoveries in this field make their way into the world of drug patents.
As compounded medications gain popularity amid drug shortages, concerns about safety, quality, and regulation have intensified, making Pharmacy Compounding Accreditation Board (PCAB) accreditation a safeguard for consistency, oversight, and public trust in compounding pharmacy practices.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up. We expect to promenade with the official mascots and catch up on our reading, but are, otherwise, open to suggestion.
Also, compounding pharmacies fire back at Novo Nordisk for its assertion that GLP-1 drugs are too difficult to compound. Lots today on GLP-1s: First we see tirzepatide outperforming semaglutide in a head-to-head study in obesity. Also, a Michael Gilman company pivots and more. Read the rest…
Food and Drug Administration wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies that have fueled widespread use of the knockoffs have other plans , The Wall Street Journal writes. And some pharmacies making the GLP-1 drug copycats will continue.
” Experts told STAT there’s been a surge of interest for these compounds from biotech and pharma in the last few months, spurred on most by the presentation of promising clinical data from Summit Therapeutics.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so predictable routine of online meetings, phone calls, and deadlines has returned. But you knew this would happen, yes? The world, such as it is, continues to spin.
Source: [link] Deuterated compounds have vital uses in high-tech industries such as fiber optics, semiconductors, OLEDs, defence and pharmaceuticals. With TDB’s support, Clearsynth Labs aims to create a facility that will make India a supplier of high-value deuterated compounds.
An ordered pharmaceutical compounding process for use in 503A pharmacies, 503B outsourcing facilities, pharmaceutical industry, and other applications.
Pharmacy leaders from Cone Health discuss how robotic compounding technologies have improved safety, accuracy, and reliability in hazardous and sterile medication preparation across oncology and acute care settings.
The center is designed to support centralized medication repackaging, sterile compounding at scale, home infusion services, streamlined logistics and standardized operations across locations. Luke’s. The post St.
Nearly 88% cited shortages of experienced pharmacy technicians and more than 92% reported shortages of sterile-compounding technicians. Despite the growth, hospitals report significant challenges across the pharmacy workforce. The survey included responses from 250 hospitals, with results weighted to provide national estimates.
billion in 2022 and is expected to grow at a compound annual growth rate of 5.3% The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 from 2023 to 2030.
AI models can predict molecular interactions and assist in designing novel compounds tailored to specific therapeutic goals. AI-driven screening methods, such as High-Throughput Screening (HTS), allow researchers to rapidly evaluate large libraries of compounds.
.” Chairing a session titled, CEO’s Vision on Sustainable quality, Mehul Shah, honorary Secretary General, IDMA and CMD, Encube Ethicals alluded to the ”power of compounding” in India’s pharma industry but also made the point that quality is a challenge, unless the sector transitions from reactive to proactive regulatory (..)
From initial compound discovery to formulation improvements, every step offers opportunities for patent protection.” A: A composition of matter patent covers the drug compound itself, while a formulation patent covers specific formulations or dosage forms of the drug.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
There are limitations of current approaches for synthesising propranolol, a key compound for management of cardiovascular conditions , Fu et al. According to their findings, the innovative amine-functionalised graphene oxide (NGO) membrane reactor enabled nearly 100 percent conversion and selectivity in under 4.63 seconds at 23 °C.
per cent compound annual growth rate (CAGR) from $13.5 With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at a 9.6 billion in 2022 to $33.7 billion in 2032 across the seven major markets (7MM*), forecasts GlobalData.
This effort is essential to pharmacology and drug discovery, where varying conventions across sources often result in the same compound being described in different ways. This process unifies different substance representations, synonyms, and identifiers into a single, consistent entity.
Undefined terms like “undue delay” and “disproportionate effort” add layers of uncertainty, which are further compounded by the fact that enforcement will rely on varying capacities and interpretations, as the EU relies on 27 independent data protection authorities 3 to enforce regulations.
In a rodent pharmacokinetic study, both compounds […] The post Neurizon confirms positive results for prospective ALS treatment appeared first on Pharmafile.
In a groundbreaking development, researchers have successfully used AI to design novel compounds with unprecedented efficacy. As the pharmaceutical industry grapples with the rise of generative AI, a new question is emerging: who owns the rights to medicines designed by machines? Read the full story: [link] "
The ad, asking patients to “be a healthy skeptic,” was released soon after a commercial from telehealth firm Hims & Hers, selling a compounded weight loss drug, premiered at the Super Bowl. Continue to STAT+ to read the full story…
This new vancomycin is the only FDA-approved product that can be used directly from room temperature storage, eliminating the need for compounding, thawing, activation, or dilution. This innovation aims to expedite treatment by reducing preparation steps.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content